Guided Therapeutics Inc. (OTCMKTS:GTHP) Sees Significant Decrease in Short Interest

Guided Therapeutics Inc. (OTCMKTS:GTHPGet Free Report) was the target of a significant decrease in short interest in July. As of July 15th, there was short interest totaling 1,437 shares, a decrease of 92.7% from the June 30th total of 19,653 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily volume of 29,293 shares, the days-to-cover ratio is presently 0.0 days.

Guided Therapeutics Stock Performance

Guided Therapeutics stock opened at $0.25 on Friday. The firm’s 50 day moving average price is $0.24 and its two-hundred day moving average price is $0.28. Guided Therapeutics has a twelve month low of $0.12 and a twelve month high of $0.54. The firm has a market cap of $24.43 million, a PE ratio of -6.33 and a beta of 0.72.

Guided Therapeutics (OTCMKTS:GTHPGet Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Guided Therapeutics Company Profile

(Get Free Report)

Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S.

Further Reading

Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.